Town & Country Bank & Trust CO dba First Bankers Trust CO held its stake in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 3,867 shares of the medical research company’s stock at the end of the second quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Amgen were worth $666,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Mascoma Wealth Management LLC raised its stake in shares of Amgen by 193.3% in the second quarter. Mascoma Wealth Management LLC now owns 1,525 shares of the medical research company’s stock valued at $263,000 after acquiring an additional 1,005 shares during the last quarter. Hallmark Capital Management Inc. raised its stake in shares of Amgen by 0.8% in the second quarter. Hallmark Capital Management Inc. now owns 92,766 shares of the medical research company’s stock valued at $15,977,000 after acquiring an additional 722 shares during the last quarter. St. Johns Investment Management Company LLC raised its stake in shares of Amgen by 5.1% in the second quarter. St. Johns Investment Management Company LLC now owns 8,454 shares of the medical research company’s stock valued at $1,456,000 after acquiring an additional 411 shares during the last quarter. Chesley Taft & Associates LLC raised its stake in shares of Amgen by 4.4% in the second quarter. Chesley Taft & Associates LLC now owns 8,367 shares of the medical research company’s stock valued at $1,441,000 after acquiring an additional 350 shares during the last quarter. Finally, Leavell Investment Management Inc. raised its stake in shares of Amgen by 17.9% in the second quarter. Leavell Investment Management Inc. now owns 13,406 shares of the medical research company’s stock valued at $2,309,000 after acquiring an additional 2,035 shares during the last quarter. Hedge funds and other institutional investors own 78.10% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Amgen Inc. (AMGN) Stake Held by Town & Country Bank & Trust CO dba First Bankers Trust CO” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/05/amgen-inc-amgn-stake-held-by-town-country-bank-trust-co-dba-first-bankers-trust-co.html.

Shares of Amgen Inc. (AMGN) traded down 1.39% during trading on Thursday, reaching $185.96. 2,734,976 shares of the company were exchanged. The firm has a market cap of $135.69 billion, a price-to-earnings ratio of 16.94 and a beta of 1.36. The stock’s 50-day moving average is $180.38 and its 200-day moving average is $169.99. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $191.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted $2.84 earnings per share. Equities research analysts predict that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.44%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is 41.93%.

A number of research analysts have recently issued reports on AMGN shares. Sanford C. Bernstein set a $164.00 target price on shares of Amgen and gave the company a “hold” rating in a research note on Thursday, June 8th. Morgan Stanley lifted their target price on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. set a $189.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, June 13th. UBS AG reiterated a “neutral” rating and issued a $175.00 target price (up previously from $174.00) on shares of Amgen in a research note on Tuesday, June 13th. Finally, Leerink Swann restated a “market perform” rating and issued a $161.00 price objective on shares of Amgen in a research report on Thursday, June 22nd. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and an average price target of $189.35.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.